[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-ptsd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-ptsd":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100545753","phase-2-psilocybin-assisted-cognitive-processing-therapy-for-chronic-ptsd-100545753",false,"NCT06386003","Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial","Inclusion Criteria:\n\n1. Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;\n2. Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;\n3. Are willing to refrain from taking any psychiatric medications during the study period.\n\nExclusion Criteria:\n\n1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;\n2. Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;\n3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;\n4. Have hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 or higher assessed on three separate occasions;\n5. History of seizure disorder;\n6. Uncontrolled insulin-dependent diabetes;\n7. Recent stroke, intracranial or subarachnoid hemorrhage (\\\u003C 1 year from signing of informed consent form \\[ICF\\]), recent myocardial infarction (\\\u003C 1 year from signing of ICF), clinically significant arrhythmia (\\\u003C 1 year from signing of ICF);\n8. Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;\n9. Lifetime history of substance-induced psychosis;\n10. Lifetime history of substance use disorder with a hallucinogen;\n11. History of alcohol use disorder in the past 3 months.","ALL","18 Years","65 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).",[27,28,29],"Post Traumatic Stress Disorder","PTSD","Chronic PTSD",[27,31,32],"Psilocybin","Cognitive Processing Therapy","RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2027-01",{"name":43,"class":44},"Unity Health Toronto","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100523519","psychotherapy-effects-on-reward-processing-in-ptsd-100523519","NCT06096740","Psychotherapy Effects on Reward Processing in PTSD","The Effects of Trauma-focused Psychotherapy on Reward Circuitry Function and Information Encoding","PERPP","Inclusion Criteria:\n\n* English as primary language, and comprehension suitable to understand experimenter instructions.\n* Current and chronic syndromic PTSD, defined as being exposed to a DSM-5 Criterion A traumatic event, with the presence DSM-5 qualifying PTSD symptoms for at least 3 months, as assessed by the Clinician-Administered PTSD Scale for DSM-5.\n* Able and willing to undergo functional magnetic resonance imaging (fMRI).\n* Willingness to participate in repeated assessments and as part of a delayed treatment group.\n\nExclusion Criteria:\n\n* Evidence of current or prior history of psychosis or bipolar disorder as evidenced by self-report or clinical interview.\n* Active substance dependence within the past 6 months as evidenced by clinical interview.\n* Current regular psychiatric medication use (i.e. antidepressants), except for as-needed benzodiazepine or opiate medication no more than three times per week, on average, or for short-duration stimulant medication for attention deficit hyperactivity disorder that can be skipped within 24 hours of study visits.\n* A recent (\\\u003C6 months) suicide attempt or current active ideation with intent.\n* Unremovable ferrous metal in body.\n* History of neurological disorder, stroke, seizures\u002Fconvulsions (except febrile seizures in childhood), epilepsy, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, or thyroid disorder.\n* Anyone who is pregnant or trying to become pregnant.\n* Current or past year (\\> 3 sessions), psychotherapy with a prominent exposure or cognitive restructuring component.\n* Previous or current (es)ketamine treatment and\u002F or brain stimulation\u002Fneuromodulation treatment.\n* Other ongoing treatment that is likely to confound experimental effects.\n* Previous penetrating head injury\u002Ftraumatic brain injury. Mild-to-moderate traumatic brain injury without penetrating injury is allowable.",{"count":55,"type":21},120,[57],"NA","The purpose of this study is to identify how trauma-focused psychotherapy changes the function of brain circuitry in posttraumatic stress disorder (PTSD) and how this mediates improvements in the diminished ability to experience positive emotions following a traumatic or extremely stressful life event. In this instance, the investigators will be using cognitive processing therapy (CPT), a widely-utilized and evidence-based treatment for PTSD.",[27,60,61,28,29,62],"Diminished Pleasure","Anhedonia","Chronic Post-Traumatic Stress Disorder",[28,64,65,66,32,67,29],"Post Traumatic Stress","Emotional Numbing","CPT","Therapy","2026-04-27",{"date":70,"type":37},"2026-05-01",{"date":72,"type":37},"2024-06-01",{"date":74,"type":21},"2029-05-01",{"name":76,"class":44},"University of Texas at Austin"]